Oncogencell Comprehensive Assay Plus
DNA and RNA are simultaneously screened in over 500 genes in solid tumors using Next Generation Sequencing (NGS) technology. Suitability for targeted smart drugs, PARP inhibitors, and immunotherapy is reported in light of NCCN and ESMO guidelines through Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Genomic Instability Metric (GIM) analyses.
Create Test RequestDecode Your Tumor's Genetic Code with a Single Test
The Oncogencell Comprehensive Assay Plus (OCA Plus) is one of the most advanced Next Generation Sequencing (NGS) panels designed to map the molecular profile of solid tumors. Unlike traditional single-gene tests, it provides a complete picture of the tumor's biology.
Maximum Genomic Coverage
Over 500 genes associated with cancer development are screened simultaneously. Thanks to the concurrent analysis of DNA and RNA, point mutations (SNV), deletions, copy number variations (CNV), and critical gene fusions are captured with maximum accuracy.
Immunotherapy and HRD Analysis
It measures not only mutations but also the TMB (Tumor Mutational Burden) and MSI (Microsatellite Instability) metrics that determine the immunotherapy response. Additionally, it offers HRD (Genomic Instability Metric - GIM) scoring as a standard for PARP inhibitors.
Targeted Therapy Guide
The massive genetic dataset obtained is processed with bioinformatics algorithms and matched with NCCN, ESMO, and FDA guidelines. The most appropriate smart drugs, chemotherapy options, and global clinical trial phases for the patient are reported.
Step-by-Step OCA Plus Analysis Process
Our optimized fast and reliable NGS workflow, designed to extract maximum data from limited tumor tissue.
1. Low Sample Requirement
A small needle biopsy taken from the patient or paraffin block (FFPE) slide sections are delivered to our laboratory for testing. The success rate is very high even with low-input samples.
2. Simultaneous Isolation
Unlike traditional methods, DNA and RNA are isolated simultaneously from precious tumor tissue. This both saves tissue and accelerates the process.
3. Deep Sequencing (NGS)
The isolated nucleic acids are transferred to high-precision chips, and over 500 genes, as well as TMB and MSI profiles, are sequenced simultaneously.
4. Clinical Bioinformatics
The resulting massive dataset is processed with advanced software, immunotherapy (HRD) scores are calculated, and a clinical report supported by international guidelines is generated.
Consult Us for Comprehensive Genomic Profiling
Get instant information from our experts about the suitability of the OCA Plus test for you or your patient, paraffin block (FFPE) submission details, and targeted analysis reporting.
Why Should You Choose the OCA Plus Test?
Going beyond traditional single-gene tests, it analyzes every aspect of the tumor's biological behavior and maximizes treatment success.
Complete Solution in a Single Test
Instead of performing separate EGFR, ALK, ROS1, and BRAF tests, it examines over 500 genes simultaneously, saving precious tumor tissue and critical time.
Immunotherapy Guidance
By determining Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) values with high accuracy, it predicts the patient's response to immunotherapy.
HRD and PARP Inhibitors
By analyzing Homologous Recombination Repair (HRR) pathway genes and the Genomic Instability Metric (GIM), it determines suitability for PARP inhibitors (targeted therapy) in ovarian, breast, and prostate cancers.
Global Guideline Integration
The results obtained are matched with up-to-date oncology guidelines such as NCCN, ESMO, FDA, and EMA, providing the physician with a directly actionable, evidence-based report.
Powerful gene content and complex biomarker detection
Oncomine Comprehensive Assay Plus covers a massive sequence of over 500 different genes, including critical oncogenes such as EGFR, BRAF, KRAS, ERBB2, and MET, as well as fusions in ALK, ROS1, RET, and NTRK1/2/3 genes. Each gene has been carefully selected by our oncology informatics experts in light of proprietary databases, academic articles, and industry data, and validated in collaboration with leading pharmaceutical companies.
Genomic Instability Metric (GIM) to assess genomic instability.
Over 1 Mb of exonic coverage for Tumor Mutational Burden (TMB) analysis.
Cellularity calculation for tumor fraction assessment.
Evaluation and profiling of mutation patterns.
MSI-H/MSS markers for sensitive Microsatellite Instability (MSI) detection.
Advanced NGS techniques for precise gene sequencing and variant detection.
Next Generation Sequencing (NGS) Frequently Asked Questions
Discover the most frequently asked questions about Next Generation Sequencing (NGS) technology, advanced genetic testing processes, and its role in modern oncological diagnosis.